A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease
Study sponsor: Mesoblast, Ltd. · MESO
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-02-28Estimated
Enrollment · participants180Estimated
Source updated2026-05-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.